The volume of patient-initiated EHR messages “increased dramatically” after the onset of the COVID-19 pandemic and remained elevated through 2022, said A. Jay Holmgren, PhD.

While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

Though President Trump denied having any connection to Project 2025 on the campaign trail, he has pushed its health policy ...

The FDA has accepted for review the resubmitted application for odronextamab to treat relapsed/refractory follicular lymphoma.

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

Recent cuts to the federal workforce could negatively impact cancer research and public health for years to come, researchers say.

HHS Secretary Robert F. Kennedy Jr. has rescinded the HHS policy of requiring new rules and regulations to be open to public comment before they are implemented.

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

As legal battles over the federal funding freeze and indirect cost payments from NIH play out in court, cancer research is being disrupted.

Appendix tumors should be evaluated separately and not included in colon or colorectal cancer categories,” researchers concluded.

A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).